Buying guide
Apple Watch vs Oura Ring 4 in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Apple | Oura |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $399-$799 (actual sale price) | $349-$499 or $70/year lease or $6/month subscription (actual sale price) |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 1Apple | 1Oura |
| Privacy practices | 13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage | 12cloud-upload, biometric-storage, data-sale, data-deletion-control, biometric-storage, data-retention, location-tracking, training-data-use, biometric-storage, data-sale, data-deletion-control, data-retention |
| Sources on file | 26 | 23 |
Editorial summaries
Apple Watch
The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.
Oura Ring 4
The Oura Ring 4 (Gen 4, late 2024, from Oura, founded 2013 in Oulu, Finland) is a titanium biometric smart ring and the study-first archetype of the biometric cohort. Its 'Smart Sensing' recessed sensors (PPG heart rate and HRV, red and infrared blood-oxygen, multi-point skin temperature, accelerometer) feed 50-plus metrics: sleep staging and Sleep Score, Readiness, Activity, stress, cycle tracking, a VO2 Max estimate, and an LLM 'Oura Advisor'. It is sold as a purchase (from about $349) plus a required Oura Membership ($5.99/month); the AI augments genuine biometric sensing rather than being the product. DEPLOY records commercial maturity and a reported $11 billion valuation (October 2025). The verified-vs-claimed throughline: Oura is positioned as general wellness and is not FDA-cleared for diagnostics, and it ran a blood-pressure study in December 2025 before marketing blood pressure, the study-first counterpoint to Whoop's market-first BP Insights. Oura is also the patent-holder in the smart-ring litigation (RingConn settled; Ultrahuman was ITC import-banned via the '178 patent).
Machine-readable: this page as markdown.